PRASUGREL

Data suggest , however , that prasugrel may reduce the risk of ischemic events in these patients .

数据显示，但是，普拉格雷可能会降低这些患者缺血事件的风险。

Patients randomly assigned to receive prasugrel received a60-mg loading dose before the procedure , followed by10 mg daily .

病人被随机安排给予普拉格雷，术前60mg负载量，之后每天10mg。

However , bleeding rates were slightly higher among patients receiving prasugrel .

然而，接受普拉格雷治疗的病人出血风险有所增加。

The trial could be crucial for the fate of prasugrel because more than half of patients treated for acute coronary syndrome do not receive stents .

这项试验对普拉格雷的命运至关重要，因为半数以上的急性冠脉综合征的患者不想安装支架。

Moreover , prasugrel therapy resulted in reductions in both early and late stent thrombosis , irrespective of stent type and in patients with a broad range of clinical and procedural characteristics .

此外，不论支架类型，在具有广泛临床特征和手术特性的病人中，普拉格雷疗法都能够降低早期和晚期的支架血栓形成。

The FDA staff also notes that patients who received prasugrel were more likely to develop cancer than those who took Plavix , though it 's not clear whether prasugrel actually raises the risk of cancer .

同时FDA文件提到接受普拉格雷治疗的患者相对接受氯比格雷治疗的患者更容易患上癌症，虽然目前不清楚是否由于使用了普拉格雷而导致癌症的产生。